

## Objective of the PREFER Annual Meeting 2018

- Provide, discuss and understand the PREFER strategy and how the results of the methods work package will shape the case studies, initial recommendations, further collaboration and communication.
- Discussions and interactions.

## High level outline of the meeting

- Two years of PREFER: what is the direction we take? Get consortium and stakeholders clear about the BIG PICTURE & STRATEGY.
  - What did we learn about stakeholder needs, expectations, desires and about patient preference methods?
  - What are the most relevant questions for case studies – supported by regulators and HTA bodies / payers? And patients.
  - What are the expected deliverables / outcomes for PREFER?
  - Celebration & thank you
- PREFER recommendations at the end of year 2
  - Task 2.9
  - Collaboration with PARADIGM
- The three core PREFER case studies
  - Clinical and methodological questions
  - Anticipated recommendations
  - Operationalization (study teams: expertise, resources, budget, timelines)
  - Engage with patients
- Simulation studies
  - ... and how they complement empirical case study results
- The concept of additional case studies
  - Call for industry and academic studies initiated by consortium partners
  - Call for other supportive studies from outside PREFER
  - PREFER point of contact for new case studies
- PREFER communication & dissemination
  - Show what we have communicated / disseminated
  - Communication strategy (impact strategy team)
  - What is planned?
  - How can everybody contribute?
  - Communication rules.

### Attendees (invited):

- Consortium
- SAB
- EAB
- PAG SAG, REG SAG, HTA SAG
- PARADIGM coordinator
- IMI Scientific officer



**@IMI\_PREFER**  
**#PREFER2years**

All presentations will be stored on ProjectPlace (Path:Documents/Project Meetings/07 Annual Meeting Leuven).

## Day 1 – Thursday, 25<sup>th</sup> October 2018

Time	Topic	Speaker	Additional information
08:30	Welcome coffee		
09:00	Welcome by host	Isabelle Huys, Wim Robberecht (CEO KUL)	
09:10	Welcome of the coordinators	Mats Hansson	
09:20	Two years of PREFER – our achievements	Mats Hansson	Highlights
09:35	Keynote speaker	Peter Mol (University Medical Center Groningen)	
09:55	Keynote speaker	Nathalie Seigneuret (IMI)	
10:15	Coffee break		Poster session
10:45	Panel discussion	Moderator: Becky Noel Panelists: Nele Caeyers, Peter Mol, Marco Petschulies, Nathalie Seigneuret and Conny Berlin	
11:30	Two years of PREFER – future direction	Conny Berlin, Jürgen Kübler, Becky Noel, Juhaeri Juhaeri, Isabelle Huys	
12:30	Group photo and lunch break		Poster session
13:30	Collaboration with PARADIGM	Jürgen Kübler, Mathieu Boudes	
14:00	Introduction to case studies	Mats Hansson	
14:05	Case study Rheumatoid Arthritis <ul style="list-style-type: none"> <li>○ Clinical and methodological questions</li> <li>○ Anticipated recommendations</li> <li>○ Operationalization (study teams: expertise, resources, budget, timelines)</li> <li>○ Engage with patients, role of the patient</li> </ul>	Karim Raza, Jorien Veldwijk, Rachael DiSantostefano	

14:35	Case study Neuromuscular Disorders <ul style="list-style-type: none"> <li>o Clinical and methodological questions</li> <li>o Anticipated recommendations</li> <li>o Operationalization (study teams: expertise, resources, budget, timelines)</li> <li>o Engage with patients, role of the patient</li> </ul>	Cecilia Jimenez-Moreno, Ardine de Wit, Bennett Levitan	
15:05	Coffee break		Poster session
15:30	Simulation studies <ul style="list-style-type: none"> <li>o How they complement empirical case study results</li> </ul>	Bennett Levitan	
16:00	Discussion of RA, NMD and simulation studies	Isabelle Huys, Rosanne Janssens	
16:30	The concept of additional case studies <ul style="list-style-type: none"> <li>o Call for industry and academic studies initiated by consortium partners</li> <li>o Information on additional case study from Pfizer</li> </ul>	Sheila Dickinson, Jorien Veldwijk, Leo Russo	
17:15	Discussion of additional case studies and AOB	Sheila Dickinson, Jorien Veldwijk	
18:00	End of plenary session		
18:30	Dinner		Faculty Club, room Lemaire

## Day 2 – Friday, 26<sup>th</sup> October 2018

Time	Topic	Speaker	Additional information
08:00	Pre-meeting: PREFER strategy team meets SAB, EAB, SAG, IMI Scientific Officer	Chair: Conny Berlin and Mats Hansson	Room Bisschopskamer
09:00	Welcome & summary of day 1	Filip Mussen and Bennett Levitan	
09:15	PREFER external presence: Where established, gaps remaining	Josepine Fernow & Kristin Bullok	
09:30	PREFER impact strategy: where we are, what is needed <ul style="list-style-type: none"> <li>• Strategy for Regulators, Industry and HTA</li> <li>• Advocacy 101: What our patient partners do</li> </ul>	Kristin Bullok Valentina Strammiello	
10:00	Patient partners influence on strategy and patient communication: Brainstorming	<b>All</b> , moderated by Communications Team	
10:30	Coffee break		
11:00	Interactions (breakouts) <ol style="list-style-type: none"> <li>1. Comm Team meets Impact Strategy Team</li> <li>2. Rheumatoid Arthritis</li> <li>3. Neuromuscular Disorders</li> <li>4. Lung Cancer</li> <li>5. Additional industry case studies</li> </ol>	1. Kristin Bullok, Josepine Fernow 2. Jorien Veldwijk, Rachael DiSantostefano, Karim Raza 3. Ardine de Wit, Cecilia Jimenez-Moreno, Cathy Anne Pinto 4. Eva Katz, Angelo Paradiso, Luca Bailo, Leo Russo 5. Ulrik Kihlbom, Sheila Dickinson, Martin Gebel, Leo Russo	
13:00	Lunch break		
14:00	Wrap-up: pertinent feedback from the interactions	Moderator: Bennett Levitan	5 minutes summary of breakouts
14:45	Closure and next steps	Conny Berlin	
15:00	Coffee break and end of meeting		